Navigation Links
ARUP Laboratories Partners With Pathology Service Associates
Date:6/18/2008

ices will also have access to ARUP Consult, a state-of-the-art online resource providing up-to-date lab testing information and concise diagnostic advice regarding test selection and interpretation for more than 1,500 laboratory tests. Disease-specific topics with background information, test ordering suggestions, and diagnostic algorithms are co-authored and maintained by ARUP's expert panel of medical faculty and consultants and include recommendations that are congruent with and link to national guidelines and relevant references.

"PSA is pleased to offer our affiliated pathology practices special pricing on services which will assist them in maintaining a competitive advantage in their markets," said PSA President Al Sirmon. "PSA chose to partner with ARUP because of their philosophy to support their clients' existing test menus by offering highly complex and unique lab tests rather than competing for referring physician office business."

About PSA, LLC

PSA, a MED3OOO company, is the leading provider of business services and support to independent pathology practices. Focusing exclusively on pathology, PSA is unique to the business of pathology, and dedicated to providing comprehensive business solutions to visionaries and leading pathology practices seeking to gain a competitive advantage within their markets. Through an integrated approach of billing and collection services, practice marketing support, and business support services, PSA offers pathology practices the opportunity to optimize collections, facilitate additional referrals, acquire new technology at preferred pricing, and exchanging knowledge with peers across the U.S., while avoiding compliance pitfalls. The PSA network is a nationwide affiliation of pathologists who desire to run their practices as a business and provide quality community pathology. Please visit http://www.psapath.com for additional information.

About
'/>"/>

SOURCE ARUP Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
2. Cato Research and Neuland Laboratories Form Cato Research Neuland India, Ltd.
3. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
4. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
5. IDEXX Laboratories Announces First Quarter Results
6. ARUP Laboratories CEO and Co-Founder Announces Retirement
7. Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories
8. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
9. Stonegate Report About Unigene Laboratories Inc.
10. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
11. White Paper Details Environmental Health & Safety Compliance Strategies for Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Newly discovered mechanism allows cells to change state 2More than fish bait: Worms unlock secrets to new epilepsy treatments 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4PDL BioPharma to Present at Oppenheimer 26amp 3B Co 20th Annual Healthcare Conference on November 4 2009 14619 1Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 1Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 2Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 3Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 4Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 5Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 6Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 7Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 8Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 1Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 2Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 3Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 4Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 5Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 6Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 7Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 8Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 9Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 10Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 11Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 12Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 13Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 14Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 15Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 16Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 17Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 18Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 19Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 20Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 21Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 22